Alphamab Oncology
HKEX:9966.HK
Overview | Financials
Company Name | Alphamab Oncology |
Symbol | 9966.HK |
Currency | HKD |
Price | 3.87 |
Market Cap | 3,734,255,880 |
Dividend Yield | 0% |
52-week-range | 2 - 13.46 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Ting Xu Ph.D. |
Website | https://www.alphamabonc.com |
An error occurred while fetching data.
About Alphamab Oncology
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1)
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD